Gene Solutions at POGS 2025: Advancing Precision & Preventive Care

PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310 eminent gynecologists, obstetricians, fetal medicine specialists and prenatal genetics experts.

 

Throughout the event, the Gene Solutions India team & our partner, AMPATH (American Institute of Pathology and Laboratory Sciences), engaged with delegates to present the triSure™ Next-Generation NIPT portfolio, featuring comprehensive analysis of both fetal and maternal health from 10 mL of maternal blood: 

Fetal health — cell-free placental DNA analysis: 

  • Chromosomes and deletions: all aneuploidies and fivemajormicro–deletions. 
  • Dominantsingle-gene disorders: 7,018 mutations related to 25 dominantsingle-gene disorders. 

Maternal health — cell-free maternal DNA: 

  • Carrier status: 7,535 mutations related to 18 recessivesingle-genedisorders — carrier screening for the mother. 
  • Pregnancy complications: gestational diabetes mellitus (GDM) risk prediction in the first trimester.

This advanced solution is designed to support OBGYNs in both routine care and complex clinical decision-making. 

A key additional feature of the engagement was SPOTMAS, Asia’s first clinically validated multicancer early detection (MCED) test. SPOTMAS is Gene Solutions’ AI powered cell-free DNA platform for MCED and tumor-of-origin (TOO) localization across 10 cancer groups and 75 subtypes — integrating genetics, epigenetics, and fragmentomics in one streamlined workflow. 

This breakthrough innovation, which can help screen for cancers without current screening methods — such as endometrial, ovarian, pancreatic, liver, head & neck cancers — sparked strong interest and meaningful discussions among attending delegates. 

The experience at POGS 2025 reflects Gene Solutions’ ongoing journey toward advancing precision medicine and preventive healthcare in India. We appreciate this value opportunity and look ahead to continued collaboration and shared learning. 

LATEST News

ESMO 2026 Gene Solutions Global Industry Satellite Symposium AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

MADRID, Nov. 18, 2026 — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies span ning cancer screening, precision oncology, and functional applications.     ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a

Read More
Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation.  The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology.  Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong,

Read More
New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More